Inflammatory mediator regulates diarrhea in IBD
NEW YORK New research indicates that the activation of an inflammatory mediator in the human body may cause diarrhea in people suffering from inflammatory bowel disease.
Researchers led by Terrence A. Barrett of Northwestern University Medical School in Chicago have discovered that activation of NF-?B results in diarrhea in IBD. IBD, which affects approximately 1-in-500 people in the United States, describes a group of diseases, including Crohn’s disease and ulcerative colitis, with inflammation in the intestinal tract. Patients with IBD experience diverse symptoms, including abdominal pain, vomiting, diarrhea, bloody stools, and weight loss.
Until now, the response of NF-?B, a protein complex, has never been completely understood. The researchers discovered, however, following immune activation, blocking NF-?B expression in the cells lining the intestinal tract inhibited diarrhea and prevented protein changes in these cells, resulting in decreased leakiness between the cells. These findings suggested that immune cell-mediated activation of in IBD promotes the movement of fluid into the bowel lumen, resulting in diarrhea.
The results were presented in the Jan. 2010 issue of the American Journal of Pathology.
Tylenol Arthritis caplet recall becomes a bigger headache
NEW YORK Johnson & Johnson has expanded its voluntary recall of Tylenol Arthritis caplets in the wake of consumer reports of a moldy smell that can cause nausea and sickness. The recall now includes all product lots of the Arthritis Pain caplet 100-count bottles with the red EZ-Open cap.
Prior to this, the company had recalled five lots of the product in November, citing similar reasons, with user complaints of nausea, stomach pain, vomiting and diarrhea.
According to J&J, the odor is coming from trace amounts of 2,4,6-tribromoanisole — a chemical used to treat wooden pallets that transport and store packaging materials — which is believed to be the result from the breakdown of another chemical used in the manufacture of the drug.
To date, the side effects have been “temporary and non-serious,” although the health effects of the compound have not been studied.
The recall only affects the specific lots reported, and does not extend to any other Tylenol pain products.
J&J is moving its production of Tylenol Arthritis Pain caplets 100-count to another plant, and plans to reintroduce the product in January.
J&J is advising consumers seeking a refund or replacement to call (888) 222-6036.
P&G adds new products to Vicks DayQuil line
CINCINNATI Procter & Gamble on Wedneday introduced Vicks DayQuil Mucus Control and DayQuil Mucus Control DM. These products, which work for four hours, help loosen and thin mucus.
Vicks DayQuil Mucus Control provides mucus relief, making coughs more productive. In addition, DayQuil Mucus Control DM contains a cough suppressant for combined comfort of thinning mucus and controlling cough.
“When you are sick, your body produces excess mucus, which also becomes thicker and more difficult to clear,” stated Matt Kemme, brand manager, Vicks. “We’ve uncovered an insight that some consumers are restricting their mucus treatment to avoid coughing up phlegm in public,” he said. “The expectorant agent in Vicks DayQuil Mucus Control acts for four hours, helping people control over when and where they expel their mucus out.”
Average retail price ranges between $6.49 and $7.29.